SEARCH

SEARCH BY CITATION

References

  • 1
    Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30:642649.
  • 2
    Poupon R, Poupon RE, Calmus Y, Chretien Y, Ballet F, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1:834836.MEDLINE
  • 3
    Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hubner K, Hellstern A, Gatzen M, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97:12681274.MEDLINE
  • 4
    Mijayi K, Akiyama T, Ito M, Urakawa T, Shimaji Y. The effect of ursodeoxycholic acid on liver functions in patients with chronic liver disease. A double blind study in one institution and the study on the effect on hepatic blood flow. Rinsho to Kenkyu 1976; 53:13951403.
  • 5
    Yamanaka M, Oto M, Obata H, Shimizu M, Sugata F, Hatta Y, Dohi Y, et al. The examination of the therapeutic efficacy of ursodeoxycholic acid on chronic hepatitis. A double blind study. Shindan to Chiryo 1976; 64:21502157.
  • 6
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884890.MEDLINE
  • 7
    Shoda M. Über die Ursodesoxycholsäure aus Bärengallen und ihre physiologische Wirkung. J Biochem 1927; 7:505510.
  • 8
    Kitani K. Hepatoprotective effect of ursodeoxycholate in experimental animals. In: PaumgartnerG, StiehlA, BarbaraL, RodaE, eds. Strategies For the Treatment of Hepatobiliary Diseases. Lancaster: Kluwer. 1990;4356.
  • 9
    Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994; 204(Suppl):115.
  • 10
    Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98:424428.MEDLINE
  • 11
    Marteau P, Chazouilleres O, Myara A, Jian R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990; 12:12061208.MEDLINE
  • 12
    Eusufzai S, Ericsson S, Cederlund T, Einarsson K, Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 1991; 32:10441048.MEDLINE
  • 13
    Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Effect of ursodeoxycholic acid on kinetics of major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992; 15:603608.MEDLINE
  • 14
    Rudolph G, Endele R, Senn M, Stiehl A. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology 1993; 17:10281032.MEDLINE
  • 15
    Mazzella G, Parini P, Bazzoli F, Villanova N, Festi D, Aldini R, Roda A, et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993; 38:896902.MEDLINE
  • 16
    Batta AK, Arora R, Salen G, Tint GS, Eskreis D, Katz S. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 1989; 30:19531962.MEDLINE
  • 17
    Crosignani A, Podda M, Battezzati PM, Bertolini E, Zuin M, Watson D, Setchell KD, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14:10001007.MEDLINE
  • 18
    Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, Bircher J, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990; 12:492497.MEDLINE
  • 19
    Poupon RE, Chretien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17:599604.MEDLINE
  • 20
    Javitt JB. Cholestasis in rats induced by taurolithocholate. Nature 1966; 210:12621263.MEDLINE
  • 21
    Kitani K, Ohta M, Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol 1985; 248:G407417.MEDLINE
  • 22
    Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100:203211.MEDLINE
  • 23
    Van Nieuwkerk CM, Oude Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van Den Bergh Weerman MA, et al. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996; 111:165171.MEDLINE
  • 24
    Holsti P. Cirrhosis of the liver induced in rabbits by gastric instillation of 3-monohydroxy-cholynic acid. Nature 1960; 186:250.
  • 25
    Greim H, Trulzsch D, Roboz J, Dressler K, Czygan P, Hutterer F, Schaffner F, et al. Mechanisms of cholestasis. 5. Bile acids in normal rat livers and in those after bile duct ligation. Gastroenterology 1972; 63:837845.MEDLINE
  • 26
    Greim H, Trulzsch D, Czygan P, Rudick J, Hutterer F, Schaffner F, Popper H. Mechanism of cholestasis. 6. Bile acids in human livers with or without biliary obstruction. Gastroenterology 1972; 63:846850.MEDLINE
  • 27
    Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990; 12:12161221.MEDLINE
  • 28
    Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 1986; 19:5769.MEDLINE
  • 29
    Hofmann AF. Bile acid hepatotoxicity and the rationale of UDCA therapy in chronic cholestatic liver disease: some hypotheses. In: PaumgartnerG, StiehlA, BarbaraL, RodaE, eds. Strategies for the Treatment of Hepatobiliary Diseases. Lancaster: Kluwer. 1990;1333.
  • 30
    Reichen J, Simon R. Cholestasis. In: AriasIM, BoyerJL, FaustoN, JakobyWB, SchachterDA, ShafritzDA, eds. The Liver. Biology and Pathobiology. New York: Raven Press. 1994;12911326.
  • 31
    Patel T, Spivey J, Vadakekalam J, Gores GJ. Apoptosis—an alternative mechanism of bile salt hepatotoxicity. In: PaumgartnerG, BeuersU, eds. Bile Acids in Liver Diseases. Lancaster: Kluwer. 1995;8895.
  • 32
    Kitani K, Kanai S. Tauroursodeoxycholate prevents taurocholate-induced cholestasis. Life Sci 1982; 30:515523.MEDLINE
  • 33
    Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12:486491.MEDLINE
  • 34
    Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991; 14:920926.MEDLINE
  • 35
    Schölmerich J, Baumgartner U, Miyai K, Gerok W. Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver. J Hepatol 1990; 10:280283.MEDLINE
  • 36
    Baumgartner U, Schölmerich J, Sellinger M, Reinhardt M, Ruf G, Farthmann EH. Different protective effects of tauroursodeoxycholate, ursodeoxycholate, and 23-methyl-ursodeoxycholate against taurolithocholate-induced cholestasis. Dig Dis Sci 1996; 41:250255.MEDLINE
  • 37
    Tsukahara K, Kanai S, Ohta M, Kitani K. Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats. Liver 1993; 13:262269.MEDLINE
  • 38
    Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75:451462.MEDLINE
  • 39
    Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104:17361744.MEDLINE
  • 40
    Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994; 106:13331341.MEDLINE
  • 41
    Heuman DM. Disruptive and protective interactions of bile salts, cholesterol: lecithin vesicles, and canalicular membranes. In: HofmannAF, PaumgartnerG, StiehlA, eds. Bile Acids in Gastroenterology. Lancaster: Kluwer. 1995;283289.
  • 42
    Heuman DM, Bajaj RS, Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J Lipid Res 1996; 37:562573.MEDLINE
  • 43
    Jazrawi RP, de Caestecker JS, Goggin PM, Britten AJ, Joseph AE, Maxwell JD, Northfield TC, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106:134142.MEDLINE
  • 44
    Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995; 23:283289.MEDLINE
  • 45
    Ohiwa T, Katagiri K, Hoshino M, Hayakawa T, Nakai T. Tauroursodeoxycholate and tauro-beta-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content. Hepatology 1993; 17:470476.MEDLINE
  • 46
    Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324:15481554.MEDLINE
  • 47
    Heathcote EJ, Cauch Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19:11491156.MEDLINE
  • 48
    Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:12841290.MEDLINE
  • 49
    Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759766.MEDLINE
  • 50
    Beuers U, Spengler U, Kruis W, Aydemir Ü, Wiebecke B, Heldwein W, Weinzierl M, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A double-blind, placebo-controlled trial. Hepatology 1992; 16:707714.MEDLINE
  • 51
    Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336:691695.MEDLINE
  • 52
    Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15:677684.MEDLINE
  • 53
    Müller M, Jansen PL. The secretory function of the liver: new aspects of hepatobiliary transport. J Hepatol 1998; 28:344354.MEDLINE
  • 54
    Benedetti A, Strazzabosco M, Ng OC, Boyer JL. Regulation of activity and apical targeting of the Cl/HCO3 exchanger in rat hepatocytes. Proc Natl Acad Sci U S A 1994; 91:792796.MEDLINE
  • 55
    Boyer JL, Soroka CJ. Vesicle targeting to the apical domain regulates bile excretory function in isolated rat hepatocyte couplets. Gastroenterology 1995; 109:16001611.MEDLINE
  • 56
    Crawford JM. Role of vesicle-mediated transport pathways in hepatocellular bile secretion. Semin Liver Dis 1996; 16:169189.MEDLINE
  • 57
    Larkin JM, Palade GE. Transcytotic vesicular carriers for polymeric IgA receptors accumulate in rat hepatocytes after bile duct ligation. J Cell Sci 1991; 98:205216.MEDLINE
  • 58
    Barr VA, Hubbard AL. Newly synthesized hepatocyte plasma membrane proteins are transported in transcytotic vesicles in the bile duct-ligated rat. Gastroenterology 1993; 105:554571.MEDLINE
  • 59
    Beuers U, Nathanson MH, Isales CM, Boyer JL. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis. J Clin Invest 1993; 92:29842993.MEDLINE
  • 60
    Häussinger D, Saha N, Hallbrucker C, Lang F, Gerok W. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver. Biochem J 1993; 291:355360.MEDLINE
  • 61
    Crawford JM, Strahs DC, Crawford AR, Barnes S. Role of bile salt hydrophobicity in hepatic microtubule-dependent bile salt secretion. J Lipid Res 1994; 35:17381748.MEDLINE
  • 62
    Beuers U, Throckmorton DC, Anderson MS, Isales CM, Thasler W, Kullak-Ublick GA, Sauter G, et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996; 110:15531563.MEDLINE
  • 63
    Schliess F, Kurz AK, vom Dahl S, Häussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 1997; 113:13061314.MEDLINE
  • 64
    Burgoyne RD, Morgan A. Regulated exocytosis. Biochem J 1993; 293:305316.MEDLINE
  • 65
    Nathanson MH, Boyer JL. Mechanisms and regulation of bile secretion. Hepatology 1991; 14:551566.MEDLINE
  • 66
    Beuers U, Nathanson MH, Boyer JL. Effects of tauroursodeoxycholic acid on cytosolic Ca++ signals in isolated rat hepatocytes. Gastroenterology 1993; 104:604612.MEDLINE
  • 67
    Bouscarel B, Fromm H, Nussbaum R. Ursodeoxycholate mobilizes intracellular Ca++ and activates phosphorylase a in isolated hepatocytes. Am J Physiol 1993; 264:G243G251.MEDLINE
  • 68
    Beuers U, Thiel M, Bardenheuer H, Paumgartner G. Tauroursodeoxycholic acid inhibits the cytosolic Ca++ increase in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine. Biochem Biophys Res Commun 1990; 171:11151121.MEDLINE
  • 69
    Bouscarel B, Gettys TW, Fromm H, Dubner H. Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: a role for PKC. Am J Physiol 1995; 268:G300G310.MEDLINE
  • 70
    Stravitz RT, Rao YP, Vlahcevic ZR, Gurley EC, Jarvis WD, Hylemon PB. Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7α-hydroxylase. Am J Physiol 1996; 271:G293G303.MEDLINE
  • 71
    Roman R, Schlenker T, Fitz JG. Ursodeoxycholic acid activates Ca2+-dependent Cl currents in a human biliary cell line. In: PaumgartnerG, StiehlA, GerokW, eds. Bile Acids in Hepatobiliary Diseases. Lancaster: Kluwer Academic Publishers. 1997;219223.
  • 72
    Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11:1215.MEDLINE
  • 73
    Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, Poupon R, et al. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 1992; 102:13711377.MEDLINE
  • 74
    Hillaire S, Boucher E, Calmus Y, Gane P, Ballet F, Franco D, Moukthar M, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994; 107:781788.MEDLINE
  • 75
    Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:17.MEDLINE
  • 76
    Christensen E, Altman DG, Neuberger J, De Stavola BL, Tygstrup N, Williams R. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology 1993; 105:18651876.MEDLINE
  • 77
    Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20:5764.MEDLINE
  • 78
    Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, LaRusso NF, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992; 103:18931901.MEDLINE
  • 79
    Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610615.MEDLINE
  • 80
    Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, Theilmann L, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997; 26:560566.MEDLINE
  • 81
    Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, Liepins J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27:10221028.MEDLINE
  • 82
    Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996; 23:14841490.MEDLINE
  • 83
    Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis–associated liver disease. Hepatology 1998; 27:166174.MEDLINE
  • 84
    van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, van Berge Henegouwen GP. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997; 32:369373.MEDLINE
  • 85
    Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, Sokal EM, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25:519523.MEDLINE
  • 86
    Balistreri WF, Setchell KD, Ryckman FC. Bile acid therapy in paediatric liver disease. In: PaumgartnerG, StiehlA, GerokW, eds. Bile Acids and the Hepatobiliary System. UDCA Study Group. London: Kluwer Academic Publishers. 1993;271282.
  • 87
    Nittono H, Tokita A, Hayashi M, Watanabe T, Obinata K, Nakatsu N, Miyano T, et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. Biomed Pharmacother 1989; 43:3741.MEDLINE
  • 88
    Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996; 111:716719.MEDLINE
  • 89
    Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116:624629.MEDLINE
  • 90
    Pageaux GP, Blanc P, Perrigault PF, Navarro F, Fabre JM, Souche B, Domergue J, et al. Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 1995; 23:119122.MEDLINE
  • 91
    Keiding S, Hockerstedt K, Bjoro K, Bondesen S, Hjortrup A, Isoniemi H, Erichsen C, et al. The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. Transplantation 1997; 63:15911594.MEDLINE
  • 92
    Barnes D, Talenti D, Cammell G, Goormastic M, Farquhar L, Henderson M, Vogt D, et al. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology 1997; 26:853857.MEDLINE
  • 93
    Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, Turlin B, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21:322327.MEDLINE
  • 94
    Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90:263269.MEDLINE
  • 95
    Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, Merlini R, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993; 19:459464.MEDLINE